Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies.
Identifieur interne : 003B10 ( PubMed/Corpus ); précédent : 003B09; suivant : 003B11Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies.
Auteurs : Hanan Helmy ; Gary J. Weil ; Abou Sree T. Ellethy ; Ehab S. Ahmed ; Maged El Setouhy ; Reda M R. RamzySource :
- Transactions of the Royal Society of Tropical Medicine and Hygiene [ 0035-9203 ] ; 2006.
English descriptors
- KwdEn :
- Adolescent, Adult, Albendazole (administration & dosage), Animals, Anthelmintics (administration & dosage), Antibodies, Helminth (blood), Antigens, Helminth (blood), Diethylcarbamazine (administration & dosage), Drug Administration Schedule, Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (immunology), Enzyme-Linked Immunosorbent Assay (methods), Female, Filaricides (administration & dosage), Humans, Immunoglobulin G (blood), Male, Microfilariae (isolation & purification), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Albendazole, Anthelmintics, Diethylcarbamazine, Filaricides.
- chemical , blood : Antibodies, Helminth, Antigens, Helminth, Immunoglobulin G.
- blood : Elephantiasis, Filarial.
- drug therapy : Elephantiasis, Filarial.
- immunology : Elephantiasis, Filarial.
- isolation & purification : Microfilariae.
- methods : Enzyme-Linked Immunosorbent Assay.
- Adolescent, Adult, Animals, Drug Administration Schedule, Female, Humans, Male, Treatment Outcome.
Abstract
Diethylcarbamazine/albendazole (DEC/ALB) therapy is widely used in mass drug administration (MDA) programmes aimed at eliminating lymphatic filariasis. We studied the effects of repeated annual treatments with DEC/ALB on Wuchereria bancrofti microfilaraemia, filarial antigenaemia and IgG4 antibodies to Bm14 antigen. Fifty-seven subjects with asymptomatic microfilaraemia were treated with one or seven daily doses of DEC/ALB at time zero. All subjects were re-treated with single-dose DEC/ALB 12, 24 and 36 months later. The two treatment groups had comparable pre-treatment microfilaria counts. Multidose treatment cleared microfilaraemia more effectively than single-dose treatment. Filarial antigen levels decreased equally in both treatment groups. Total antigen clearance was observed in 29.6%, 52.0%, 63.6% and 79.5% of subjects at 12, 24, 36 and 48 months. These clearance rates are much higher than those observed in prior treatment trials with DEC or ivermectin. Antibody levels increased 4 weeks after treatment and then slowly decreased in most subjects. Antibody tests turned negative in 20%, 35%, 39.4% and 52.5% of treated subjects at 12, 24, 36 and 48 months post treatment. These results show that the studied parameters decline at different rates and to differing degrees following DEC/ALB treatment. These findings have important implications regarding strategies for monitoring the effects of MDA in populations.
DOI: 10.1016/j.trstmh.2005.08.015
PubMed: 16414095
Links to Exploration step
pubmed:16414095Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies.</title><author><name sortKey="Helmy, Hanan" sort="Helmy, Hanan" uniqKey="Helmy H" first="Hanan" last="Helmy">Hanan Helmy</name><affiliation><nlm:affiliation>Research and Training Center on Vectors of Diseases, Faculty of Science Building, Ain Shams University, Abbassia Square, Cairo 11566, Egypt.</nlm:affiliation></affiliation></author><author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name></author><author><name sortKey="Ellethy, Abou Sree T" sort="Ellethy, Abou Sree T" uniqKey="Ellethy A" first="Abou Sree T" last="Ellethy">Abou Sree T. Ellethy</name></author><author><name sortKey="Ahmed, Ehab S" sort="Ahmed, Ehab S" uniqKey="Ahmed E" first="Ehab S" last="Ahmed">Ehab S. Ahmed</name></author><author><name sortKey="Setouhy, Maged El" sort="Setouhy, Maged El" uniqKey="Setouhy M" first="Maged El" last="Setouhy">Maged El Setouhy</name></author><author><name sortKey="Ramzy, Reda M R" sort="Ramzy, Reda M R" uniqKey="Ramzy R" first="Reda M R" last="Ramzy">Reda M R. Ramzy</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16414095</idno><idno type="pmid">16414095</idno><idno type="doi">10.1016/j.trstmh.2005.08.015</idno><idno type="wicri:Area/PubMed/Corpus">003B10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies.</title><author><name sortKey="Helmy, Hanan" sort="Helmy, Hanan" uniqKey="Helmy H" first="Hanan" last="Helmy">Hanan Helmy</name><affiliation><nlm:affiliation>Research and Training Center on Vectors of Diseases, Faculty of Science Building, Ain Shams University, Abbassia Square, Cairo 11566, Egypt.</nlm:affiliation></affiliation></author><author><name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J" last="Weil">Gary J. Weil</name></author><author><name sortKey="Ellethy, Abou Sree T" sort="Ellethy, Abou Sree T" uniqKey="Ellethy A" first="Abou Sree T" last="Ellethy">Abou Sree T. Ellethy</name></author><author><name sortKey="Ahmed, Ehab S" sort="Ahmed, Ehab S" uniqKey="Ahmed E" first="Ehab S" last="Ahmed">Ehab S. Ahmed</name></author><author><name sortKey="Setouhy, Maged El" sort="Setouhy, Maged El" uniqKey="Setouhy M" first="Maged El" last="Setouhy">Maged El Setouhy</name></author><author><name sortKey="Ramzy, Reda M R" sort="Ramzy, Reda M R" uniqKey="Ramzy R" first="Reda M R" last="Ramzy">Reda M R. Ramzy</name></author></analytic><series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title><idno type="ISSN">0035-9203</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Albendazole (administration & dosage)</term><term>Animals</term><term>Anthelmintics (administration & dosage)</term><term>Antibodies, Helminth (blood)</term><term>Antigens, Helminth (blood)</term><term>Diethylcarbamazine (administration & dosage)</term><term>Drug Administration Schedule</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (immunology)</term><term>Enzyme-Linked Immunosorbent Assay (methods)</term><term>Female</term><term>Filaricides (administration & dosage)</term><term>Humans</term><term>Immunoglobulin G (blood)</term><term>Male</term><term>Microfilariae (isolation & purification)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term><term>Antigens, Helminth</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Microfilariae</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Diethylcarbamazine/albendazole (DEC/ALB) therapy is widely used in mass drug administration (MDA) programmes aimed at eliminating lymphatic filariasis. We studied the effects of repeated annual treatments with DEC/ALB on Wuchereria bancrofti microfilaraemia, filarial antigenaemia and IgG4 antibodies to Bm14 antigen. Fifty-seven subjects with asymptomatic microfilaraemia were treated with one or seven daily doses of DEC/ALB at time zero. All subjects were re-treated with single-dose DEC/ALB 12, 24 and 36 months later. The two treatment groups had comparable pre-treatment microfilaria counts. Multidose treatment cleared microfilaraemia more effectively than single-dose treatment. Filarial antigen levels decreased equally in both treatment groups. Total antigen clearance was observed in 29.6%, 52.0%, 63.6% and 79.5% of subjects at 12, 24, 36 and 48 months. These clearance rates are much higher than those observed in prior treatment trials with DEC or ivermectin. Antibody levels increased 4 weeks after treatment and then slowly decreased in most subjects. Antibody tests turned negative in 20%, 35%, 39.4% and 52.5% of treated subjects at 12, 24, 36 and 48 months post treatment. These results show that the studied parameters decline at different rates and to differing degrees following DEC/ALB treatment. These findings have important implications regarding strategies for monitoring the effects of MDA in populations.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16414095</PMID><DateCreated><Year>2006</Year><Month>05</Month><Day>10</Day></DateCreated><DateCompleted><Year>2006</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-9203</ISSN><JournalIssue CitedMedium="Print"><Volume>100</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Transactions of the Royal Society of Tropical Medicine and Hygiene</Title><ISOAbbreviation>Trans. R. Soc. Trop. Med. Hyg.</ISOAbbreviation></Journal><ArticleTitle>Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies.</ArticleTitle><Pagination><MedlinePgn>656-62</MedlinePgn></Pagination><Abstract><AbstractText>Diethylcarbamazine/albendazole (DEC/ALB) therapy is widely used in mass drug administration (MDA) programmes aimed at eliminating lymphatic filariasis. We studied the effects of repeated annual treatments with DEC/ALB on Wuchereria bancrofti microfilaraemia, filarial antigenaemia and IgG4 antibodies to Bm14 antigen. Fifty-seven subjects with asymptomatic microfilaraemia were treated with one or seven daily doses of DEC/ALB at time zero. All subjects were re-treated with single-dose DEC/ALB 12, 24 and 36 months later. The two treatment groups had comparable pre-treatment microfilaria counts. Multidose treatment cleared microfilaraemia more effectively than single-dose treatment. Filarial antigen levels decreased equally in both treatment groups. Total antigen clearance was observed in 29.6%, 52.0%, 63.6% and 79.5% of subjects at 12, 24, 36 and 48 months. These clearance rates are much higher than those observed in prior treatment trials with DEC or ivermectin. Antibody levels increased 4 weeks after treatment and then slowly decreased in most subjects. Antibody tests turned negative in 20%, 35%, 39.4% and 52.5% of treated subjects at 12, 24, 36 and 48 months post treatment. These results show that the studied parameters decline at different rates and to differing degrees following DEC/ALB treatment. These findings have important implications regarding strategies for monitoring the effects of MDA in populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Helmy</LastName><ForeName>Hanan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research and Training Center on Vectors of Diseases, Faculty of Science Building, Ain Shams University, Abbassia Square, Cairo 11566, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weil</LastName><ForeName>Gary J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Ellethy</LastName><ForeName>Abou Sree T</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Ehab S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Setouhy</LastName><ForeName>Maged El</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Ramzy</LastName><ForeName>Reda M R</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI 35855</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trans R Soc Trop Med Hyg</MedlineTA><NlmUniqueID>7506129</NlmUniqueID><ISSNLinking>0035-9203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000909">Antibodies, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000909" MajorTopicYN="N">Antibodies, Helminth</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008842" MajorTopicYN="N">Microfilariae</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>07</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16414095</ArticleId><ArticleId IdType="pii">S0035-9203(05)00331-7</ArticleId><ArticleId IdType="doi">10.1016/j.trstmh.2005.08.015</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003B10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16414095
|texte= Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16414095" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |